Phospholamban Antibody - #AF7778

>>买2送1 已结束>>
>>赠JD卡 已结束>>
(3)   (5)  
产品: Phospholamban 抗体
货号: AF7778
描述: Rabbit polyclonal antibody to Phospholamban
应用: WB IF/ICC
文献验证: WB, IF/ICC
反应: Human, Mouse, Rat
预测: Pig, Bovine, Horse, Sheep, Rabbit, Dog
蛋白号: P26678
RRID: AB_2844142

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Phospholamban Antibody detects endogenous levels of total Phospholamban.
RRID:
AB_2844142
引用格式: Affinity Biosciences Cat# AF7778, RRID:AB_2844142.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Cardiac phospholamban; CMD1P; CMH18; PLB; Pln; PPLA_HUMAN;

抗原和靶标

免疫原:

A synthesized peptide derived from human Phospholamban, corresponding to a region within the internal amino acids.

基因/基因ID:
PLN(5350)

研究领域

· Environmental Information Processing > Signal transduction > Calcium signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Human Diseases > Cardiovascular diseases > Dilated cardiomyopathy (DCM).

· Organismal Systems > Circulatory system > Adrenergic signaling in cardiomyocytes.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

文献引用

1). Over-expression of Kv4. 3 gene reverses cardiac remodeling and transient-outward K+ current (Ito) reduction via CaMKII inhibition in myocardial infarction. Biomedicine & Pharmacotherapy, 2020 (PubMed: 33254430) [IF=6.9]

Application: WB    Species: rat    Sample: Heart

Fig. 6. Overexpression of Kv4.3 reversed the activation of CaMKII induced by MI in vivo. (A) Representative proteins of phospho-PLB(Thr17), PLB, phospho-CaMKII, CaMKII, phospho-RYR2(ser 2814), RYR2, and SERCA2 detected by western blot. (B–H) Quantitative results of phospho-PLB(Thr17), PLB, phospho-CaMKII, CaMKII, phospho-RYR2(ser 2814), RYR2, and SERCA2 in the indicated groups (n = 3). (a) SO group, (b) MI group, (c) AD-EGFP group, (d) AD-Kv4.3 group, (e) M + C group. Data are shown as mean ± SEM.
2). Interaction between A-kinase anchoring protein 5 and protein kinase A mediates CaMKII/HDAC signaling to inhibit cardiomyocyte hypertrophy after hypoxic reoxygenation. Cellular signalling, 2023 (PubMed: 36565899) [IF=4.4]

Application: IF/ICC    Species: Rat    Sample: H9C2 cardiomyocytes

Fig. 5. Low affinity AKAP5 - PKA interaction increased CaMKII activation and cellular hypertrophy. (A) Co-localization of AKAP5 with PKA in H9C2 cardiomyocytes; Scale bar indicates 20 μm. (B) Co-localization of AKAP5 with PLN in H9C2 cardiomyocytes; Scale bar indicates 20 μm. (C) Immunoprecipitation of AKAP5 with PKA and PLN in H9C2 cardiomyocytes in each group; Two-tailed Student's t-test was performed, means ± SD (n = 3); *P < 0.05 and **P < 0.01 vs. the CON group; *P < 0.05 and **P < 0.01 vs. the H/R group; CON, normal control group; H/R, hypoxia-reoxygenation group; siAKAP5, siRNA-AKAP5 transfection group; AKAP5, A-kinase anchoring protein 5; PKA, protein kinase A; PLN, phospholamban.

Application: WB    Species: Rat    Sample: H9C2 cardiomyocytes

Fig. 5. Low affinity AKAP5 - PKA interaction increased CaMKII activation and cellular hypertrophy. (A) Co-localization of AKAP5 with PKA in H9C2 cardiomyocytes; Scale bar indicates 20 μm. (B) Co-localization of AKAP5 with PLN in H9C2 cardiomyocytes; Scale bar indicates 20 μm. (C) Immunoprecipitation of AKAP5 with PKA and PLN in H9C2 cardiomyocytes in each group; Two-tailed Student's t-test was performed, means ± SD (n = 3); *P < 0.05 and **P < 0.01 vs. the CON group; *P < 0.05 and **P < 0.01 vs. the H/R group; CON, normal control group; H/R, hypoxia-reoxygenation group; siAKAP5, siRNA-AKAP5 transfection group; AKAP5, A-kinase anchoring protein 5; PKA, protein kinase A; PLN, phospholamban.
3). A-kinase Anchoring Protein 5 Anchors Protein Kinase A to Mediate PLN/SERCA to Reduce Cardiomyocyte Apoptosis Induced by Hypoxia and Reoxygenation. Biochemistry and Cell Biology, 2022 (PubMed: 35041539) [IF=2.4]

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.